CSIMarket
 
Lineage Cell Therapeutics Inc   (NYSE: LCTX)
 

Lineage Cell Therapeutics Inc's Customers Performance

LCTX



 
LCTX's Source of Revenues During the corresponding time, Lineage Cell Therapeutics Inc saw a revenue deteriorated by -61.34 % year on year, sequentially revenue fell by -38.03 %. While revenue at the Lineage Cell Therapeutics Inc 's corporate clients

List of LCTX Customers




for the same period Lineage Cell Therapeutics Inc revnue deteriorated by -61.34 % year on year, sequentially revenue fell by -38.03 %.

List of LCTX Customers

Lineage Cell Therapeutics Inc's Business Units
Collaboration Revenues    235.55 % of total Revenue
Royalties license and other revenues    25.82 % of total Revenue
Upfront License Fees    98.97 % of total Revenue






Lineage Cell Therapeutics Inc's Comment on Sales, Marketing and Customers



The company's customers include entities that bill federal healthcare programs for products such as drugs, devices, biologics, and medical supplies eligible for payment under Medicare, Medicaid, or the Children’s Health Insurance Program. Market segments served encompass physicians—including doctors, dentists, optometrists, podiatrists, and chiropractors—certain other healthcare professionals such as physician assistants and nurse practitioners, as well as teaching hospitals. The company also serves private third-party payers and private insurers involved in healthcare benefit programs.





Lineage Cell Therapeutics Inc’s Comment on Sales, Marketing and Customers


The company's customers include entities that bill federal healthcare programs for products such as drugs, devices, biologics, and medical supplies eligible for payment under Medicare, Medicaid, or the Children’s Health Insurance Program. Market segments served encompass physicians—including doctors, dentists, optometrists, podiatrists, and chiropractors—certain other healthcare professionals such as physician assistants and nurse practitioners, as well as teaching hospitals. The company also serves private third-party payers and private insurers involved in healthcare benefit programs.








LCTX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Lineage Cell Therapeutics Inc 277.16 14.78 -64.01 77
SUBTOTAL 0.00 0.00 0.00 -

Sources: Lineage Cell Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Lineage Cell Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Lineage Cell Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.